RQC for Alzheimer's Disease

Overseen By Nicholas M Pfahler

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Zaparackas and Knepper LTD

Must not be taking: Anti-Aβ antibodies

Disqualifiers: Cognitive impairment, Hepatic disease, Kidney disease, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 6

Duration: 24 months

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines whether a mix of natural compounds—resveratrol, quercetin, and curcumin (RQC)—can slow or stop the buildup of harmful proteins in the eye and prevent memory decline in individuals with early Alzheimer's. The study compares the effects of taking RQC daily for two years against taking curcumin occasionally. It seeks volunteers in the early stages of Alzheimer's who can participate in the study's daily routine. Those with mild memory issues but no significant cognitive impairment may find this trial suitable. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important early findings.

Will I have to stop taking my current medications?

The trial requires that you do not take pharmaceutical anti-amyloid-β monoclonal antibodies like Leqembi or Aduhelm. Other medications are not specifically mentioned, so it's best to discuss your current medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that resveratrol, quercetin, and curcumin (RQC) have been tested for safety in people. One study on these ingredients for treating age-related macular degeneration found the treatment to be generally well-tolerated over two years. Additionally, high doses of resveratrol alone (up to 2 grams daily) have been found safe.

These findings suggest that RQC is likely safe for people, with no major safety concerns reported so far. However, as this trial is in an early stage, ongoing research will continue to assess its safety and tolerability. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Unlike standard Alzheimer's treatments that often focus on managing symptoms or slowing progression through neurotransmitter modulation, the RQC treatment is unique because it combines resveratrol, quercetin, and curcumin, which are compounds believed to have antioxidant and anti-inflammatory properties. Researchers are excited about this combination because it targets retinal amyloid-β, a new approach that could provide insights into Alzheimer's pathology. This method might offer a fresh perspective on early detection and intervention, potentially slowing or altering the disease's course in ways current treatments do not.

What evidence suggests that this trial's treatments could be effective for Alzheimer's disease?

This trial will compare two treatments for Alzheimer's disease. One treatment arm involves a mix of resveratrol, quercetin, and curcumin (RQC). Studies suggest this combination might reduce damage to brain cells. Resveratrol is known to protect the brain by activating certain proteins. Early findings indicate that RQC might slow memory and thinking problems and prevent harmful protein buildup.

The other treatment arm involves curcumin alone. Research suggests curcumin can attach to amyloid-β, a protein linked to Alzheimer's, potentially aiding in its detection and tracking in the eye. Although more research is needed, these compounds show promise in supporting brain health and possibly slowing Alzheimer's progression. ^{2 3 4 6 7}

Who Is on the Research Team?

Paul A Knepper, MD, PhD

Principal Investigator

Northwestern University

Are You a Good Fit for This Trial?

Adults aged 50-90 with early-stage Alzheimer's (Stage 1 or 2) are eligible for this trial. They should be able to take oral supplements and undergo eye scans using OCT. People with other serious health issues, those who can't follow the study protocol, or those allergic to the supplements' ingredients cannot participate.

Inclusion Criteria

My gender or race does not limit my participation.

Ability to speak, read, and understand English

Have adequate literacy, vision, and hearing for neuropsychological testing at screening

Exclusion Criteria

CDR-SB score > 0, indicating functional impairment

Clinically significant abnormal values in hematology, coagulation and platelet function, clinical chemistry, or urinalysis at screening (such as those with prolonged prothrombin time (PT), anemia, low neutrophil or platelet count, elevated liver function tests, low glomerular filtration rate)

I have been diagnosed with a type of mild cognitive impairment or dementia that is not Alzheimer's.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Resveratrol, Quercetin, and Curcumin (RQC) daily for 24 months, with curcumin alone taken during the 7 days preceding each of the six study visits

24 months

6 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Curcumin
• RQC

Trial Overview

The trial is testing if a combination of resveratrol, quercetin, and curcumin (RQC), taken orally for two years, can prevent brain and eye changes linked to Alzheimer's. It will compare RQC's effects on cognitive function and retinal amyloid-β against curcumin alone.

How Is the Trial Designed?

Group I: Resveratrol, Quercetin, and Curcumin (RQC) Experimental Treatment 1 Intervention

Resveratrol, Quercetin, and Curcumin (RQC) galactomannan formulations taken orally twice daily for 24 months.

Group II: Curcumin Placebo Group 1 Intervention

Curcumin taken orally twice daily during the 7 days preceding each study visit in order to label retinal amyloid-β.

Who Is Running the Clinical Trial?

Zaparackas and Knepper LTD

Lead Sponsor

Trials

1

Recruited

200+

Northwestern University Feinberg School of Medicine

Collaborator

Trials

42

Recruited

15,500+

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06470061

RQC for the Prevention of Alzheimer's Disease and Retinal ...

The goal of this clinical trial is to evaluate whether oral resveratrol, quercetin, and curcumin (RQC) can prevent the accumulation of retinal amyloid-β ...

2.

iovs.arvojournals.org

iovs.arvojournals.org/article.aspx?articleid=2795685

The Effect of Resveratrol, Quercetin, and Curcumin (RQC) on ...

Results : Baseline SAPs were significantly increased in AMD (44.6 ± 5.7%) compared with controls (34.3 ± 6.9%, p<0.0001). After 12 months of oral treatment, ...

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12348645/

Resveratrol as a Therapeutic Agent in Alzheimer's Disease

RSV exerts strong antioxidant properties and ameliorates oxidative stress, which damages neurons in AD [75]. It activates silent information regulator-1 (SIRT1) ...

4.

clinicaltrials.gov

clinicaltrials.gov/study/NCT05062486

A Study to Evaluate the Safety and Efficacy of RQC for AMD

To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration ...

5.

trial.medpath.com

trial.medpath.com/clinical-trial/1d43657c64322f9a/randomized-phase-ii-oral-rqc-alzheimer-retinal-amyloid

RQC for the Prevention of Alzheimer's Disease and Retinal ...

The goal of this clinical trial is to evaluate whether oral resveratrol, quercetin, and curcumin (RQC) can prevent the accumulation of retinal amyloid-β ...

6.

ctv.veeva.com

ctv.veeva.com/study/a-study-to-evaluate-the-safety-and-efficacy-of-rqc-for-amd

A Study to Evaluate the Safety and Efficacy of RQC for AMD

To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration ...

7.

ctv.veeva.com

ctv.veeva.com/study/rqc-for-the-prevention-of-alzheimers-disease-and-retinal-amyloid-b

RQC for the Prevention of Alzheimer's Disease and Retinal ...

The goal of this clinical trial is to evaluate whether oral resveratrol, quercetin, and curcumin (RQC) can prevent the accumulation of ...